#USA #Class Action #San Francisco #Hagens Berman #PROCEPT BioRobotics

Important Update on PROCEPT BioRobotics Class Action

Investors in PROCEPT BioRobotics Corporation, traded under the NASDAQ symbol PRCT, are being alerted to an important upcoming date concerning a class action lawsuit. The law firm Hagens Berman Sobol Shapiro LLP has notified shareholders that September 22, 2026, marks the deadline for lead plaintiff applications in the ongoing case against the company. This lawsuit has arisen amid significant concerns over the company's sales practices and financial disclosures relating to its single-use handpiece, which is used in its proprietary Aquablation therapy for treating enlarged prostates.

The lawsuit centers on alleged misrepresentations made by PROCEPT regarding its handpiece sales, which have reportedly underperformed despite previous optimistic projections. Investors who acquired shares between February 28, 2024, and February 25, 2026, may be eligible to join this class action, with the aim of holding the company accountable for potential violations of federal securities laws.

Context Surrounding the Class Action

The central issue pertains to PROCEPT's sales practices and communications concerning its handpiece product. It is alleged that the company engaged in significant discounting tactics to artificially inflate sales figures by encouraging customers to purchase more units than needed. This practice resulted in accumulations of excess inventory that were not disclosed to investors, which in turn, raised significant red flags about the company's actual sales performance and financial health.

Key Developments in the Case

Concerns surrounding PROCEPT escalated following several disappointing sales reports. In August 2025, the company publicized its Q2 financial results, highlighting a drastic decline in handpiece sales—unexpectedly falling short of consensus estimates. Further disclosures revealed that the operational strategy had inadvertently led to a significant oversupply of handpieces, with insiders admitting that customers were managing excessive inventories. By February 2026, it became clear that unit sales had plummeted, leading to a 30% sequential decline and raising alarms about the sustainability of its sales practices.

Impact on Investors

For investors, these revelations resulted in a sharp decline in stock price, amounting to a staggering loss of over 48% following the disclosures. Hagens Berman's investigation aims to determine whether PROCEPT has been transparent in its dealings and if shareholders were fully informed about the company's sales practices and their implications. Investors are strongly encouraged to submit claims now if they have suffered significant losses or possess information that could assist in the investigation.

Additional Resources and Support

For those considering participation in this class action, Hagens Berman has provided a range of resources, including a detailed video summary that outlines the allegations against PROCEPT. Interested parties can reach out to the firm directly for more information about their legal options or to discuss potential whistleblower opportunities within the scope of the investigation.

In conclusion, the upcoming September 22, 2026, deadline is crucial for investors of PROCEPT BioRobotics. As the class action progresses, those affected should remain vigilant and informed about their rights and the actions they can take to recover losses amid turbulent financial disclosures and allegations of misconduct.